The animal experiment showed that both luteolin (3–10 mg/kg) and luteolin-4′-O-glucoside (20–100 mg/kg) could inhibit URAT1 expression and promote uric acid excretion in potassium oxonate-induced hyperuricemia mice [45]. The gene discussed is SLC22A12; the disease is hyperuricemia.